Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Vector1 who wrote (6113)	12/9/1998 6:15:00 PM
From: Rocketman	Respond to of 9719

<<<<<< I'll take the blame. You can't get them all. I would rather miss a trade or two than make a mistake. I am an investor by nature and not a trader. First trading requires a full time pulse on your stocks and I have a day ( and sometimes night) job. Second, for me I don't find it ineresting or fulfillng (except when I make a qick killing). >>>>>>> That still doesn't mean we can't point fingers at each other to keep the thread happy @;-) Uhhhh, we used to have BGEN, I think it is only in you PA now. Rman

To: Vector1 who wrote (6113)	12/9/1998 7:31:00 PM
From: Cytokine1	Read Replies (2) \| Respond to of 9719

<<We have a play in transplantation--BGEN>> uh, yeah, Rman is right, we put VDXXX's BGEN shares into stronger hands in May @ $44 5/8. Beautiful, crisp, dry, windy SoCal day. BTW, I just got the '49 Caddy tuned up and installed an 8-volt battery (the voltage regulator has to be tweaked also) in place of the 6-volt for surer starting power. And I've sort of arranged for the restoral of my '51 Chevy, hope to start early next year with it... C1

To: Vector1 who wrote (6113)	12/10/1998 11:25:00 AM
From: lwd	Respond to of 9719

Thursday December 10, 9:15 am Eastern Time Company Press Release SOURCE: Sepracor Inc. Sepracor Prices $300 Million Convertible Debenture Offering MARLBOROUGH, Mass., Dec. 10 /PRNewswire/ -- Sepracor Inc. (Nasdaq: SEPR - news) today announced that the Company has offered and priced a new issue of $300 million of Convertible Subordinated Debentures due 2005 (the ''Debentures''). The Debentures will have an annual interest of 7.0%, will be convertible into common stock at $124.875 per share, and will not be redeemable for three years. The Company also may issue up to an additional $45 million of Debentures pursuant to an option granted to the initial purchaser of the Debentures. The Company intends to use the proceeds from the sale of the Debentures for its ongoing preclinical and clinical trials, funding of other research and development programs, working capital and other general corporate purposes. The Debentures have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States, except pursuant to an applicable exemption from the Securities Act registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the Debentures. This press release is being issued pursuant to and in accordance with Rule 135c under the Securities Act. To receive a copy of this release or any recent release via fax, call Sepracor's automated news fax line at 1-800-758-5804 ext. 780960. SOURCE: Sepracor Inc.